Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624822 | 0.88 | HTT (0.36) | HTTAKT1AKT2AKT3P2RY12 | |
| SCHEMBL16773595 | 0.87 | PDGFRB (0.33) | PDGFRBPDGFRAFLT3KITMTNR1B | |
| SCHEMBL16773487 | 0.87 | MTNR1B (0.32) | PDGFRBPDGFRAFLT3KITMTNR1B | |
| SCHEMBL29165557 | 0.85 | MTNR1B (0.37) | HTTPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL29165554 | 0.85 | MTNR1B (0.37) | HTTPDGFRBPDGFRAFLT3KIT | |
| SCHEMBL16624825 | 0.85 | SLC15A1 (0.37) | PDGFRBKITAKT1AKT2AKT3 | |
| SCHEMBL15390086 | 0.81 | KIT (0.46) | HTTKIT | |
| SCHEMBL15390085 | 0.81 | KIT (0.46) | HTTKIT | |
| SCHEMBL1662205 | 0.77 | MAPT (0.37) | HTT | |
| SCHEMBL15391066 | 0.77 | MAPT (0.37) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309204-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | PIK3CA, DHPS, PIK3CD | HTT 1378/4885PDGFRB 370/4885PDGFRA 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.